Gilteritinib overcomes lorlatinib resistance in ALK-rearranged cancer

Resistance to ALK inhibitors such as lorlatinib often arise due to on-target mutations. Here, the authors show the multi-kinase inhibitor gilteritinib is effective against different mutations that arise during lorlatinib in ALK fusion positive lung cancer to cause resistance.

Guardado en:

Detalles Bibliográficos
Autores principales:	Hayato Mizuta, Koutaroh Okada, Mitsugu Araki, Jun Adachi, Ai Takemoto, Justyna Kutkowska, Kohei Maruyama, Noriko Yanagitani, Tomoko Oh-hara, Kana Watanabe, Keiichi Tamai, Luc Friboulet, Kazuhiro Katayama, Biao Ma, Yoko Sasakura, Yukari Sagae, Mutsuko Kukimoto-Niino, Mikako Shirouzu, Satoshi Takagi, Siro Simizu, Makoto Nishio, Yasushi Okuno, Naoya Fujita, Ryohei Katayama
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Science Q
Acceso en línea:	https://doaj.org/article/57a69b4d14e444839652b6a01ced7b32
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:57a69b4d14e444839652b6a01ced7b32
record_format	dspace
spelling	oai:doaj.org-article:57a69b4d14e444839652b6a01ced7b322021-12-02T13:15:06ZGilteritinib overcomes lorlatinib resistance in ALK-rearranged cancer10.1038/s41467-021-21396-w2041-1723https://doaj.org/article/57a69b4d14e444839652b6a01ced7b322021-02-01T00:00:00Zhttps://doi.org/10.1038/s41467-021-21396-whttps://doaj.org/toc/2041-1723Resistance to ALK inhibitors such as lorlatinib often arise due to on-target mutations. Here, the authors show the multi-kinase inhibitor gilteritinib is effective against different mutations that arise during lorlatinib in ALK fusion positive lung cancer to cause resistance.Hayato MizutaKoutaroh OkadaMitsugu ArakiJun AdachiAi TakemotoJustyna KutkowskaKohei MaruyamaNoriko YanagitaniTomoko Oh-haraKana WatanabeKeiichi TamaiLuc FribouletKazuhiro KatayamaBiao MaYoko SasakuraYukari SagaeMutsuko Kukimoto-NiinoMikako ShirouzuSatoshi TakagiSiro SimizuMakoto NishioYasushi OkunoNaoya FujitaRyohei KatayamaNature PortfolioarticleScienceQENNature Communications, Vol 12, Iss 1, Pp 1-16 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Science Q
spellingShingle	Science Q Hayato Mizuta Koutaroh Okada Mitsugu Araki Jun Adachi Ai Takemoto Justyna Kutkowska Kohei Maruyama Noriko Yanagitani Tomoko Oh-hara Kana Watanabe Keiichi Tamai Luc Friboulet Kazuhiro Katayama Biao Ma Yoko Sasakura Yukari Sagae Mutsuko Kukimoto-Niino Mikako Shirouzu Satoshi Takagi Siro Simizu Makoto Nishio Yasushi Okuno Naoya Fujita Ryohei Katayama Gilteritinib overcomes lorlatinib resistance in ALK-rearranged cancer
description	Resistance to ALK inhibitors such as lorlatinib often arise due to on-target mutations. Here, the authors show the multi-kinase inhibitor gilteritinib is effective against different mutations that arise during lorlatinib in ALK fusion positive lung cancer to cause resistance.
format	article
author	Hayato Mizuta Koutaroh Okada Mitsugu Araki Jun Adachi Ai Takemoto Justyna Kutkowska Kohei Maruyama Noriko Yanagitani Tomoko Oh-hara Kana Watanabe Keiichi Tamai Luc Friboulet Kazuhiro Katayama Biao Ma Yoko Sasakura Yukari Sagae Mutsuko Kukimoto-Niino Mikako Shirouzu Satoshi Takagi Siro Simizu Makoto Nishio Yasushi Okuno Naoya Fujita Ryohei Katayama
author_facet	Hayato Mizuta Koutaroh Okada Mitsugu Araki Jun Adachi Ai Takemoto Justyna Kutkowska Kohei Maruyama Noriko Yanagitani Tomoko Oh-hara Kana Watanabe Keiichi Tamai Luc Friboulet Kazuhiro Katayama Biao Ma Yoko Sasakura Yukari Sagae Mutsuko Kukimoto-Niino Mikako Shirouzu Satoshi Takagi Siro Simizu Makoto Nishio Yasushi Okuno Naoya Fujita Ryohei Katayama
author_sort	Hayato Mizuta
title	Gilteritinib overcomes lorlatinib resistance in ALK-rearranged cancer
title_short	Gilteritinib overcomes lorlatinib resistance in ALK-rearranged cancer
title_full	Gilteritinib overcomes lorlatinib resistance in ALK-rearranged cancer
title_fullStr	Gilteritinib overcomes lorlatinib resistance in ALK-rearranged cancer
title_full_unstemmed	Gilteritinib overcomes lorlatinib resistance in ALK-rearranged cancer
title_sort	gilteritinib overcomes lorlatinib resistance in alk-rearranged cancer
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/57a69b4d14e444839652b6a01ced7b32
work_keys_str_mv	AT hayatomizuta gilteritinibovercomeslorlatinibresistanceinalkrearrangedcancer AT koutarohokada gilteritinibovercomeslorlatinibresistanceinalkrearrangedcancer AT mitsuguaraki gilteritinibovercomeslorlatinibresistanceinalkrearrangedcancer AT junadachi gilteritinibovercomeslorlatinibresistanceinalkrearrangedcancer AT aitakemoto gilteritinibovercomeslorlatinibresistanceinalkrearrangedcancer AT justynakutkowska gilteritinibovercomeslorlatinibresistanceinalkrearrangedcancer AT koheimaruyama gilteritinibovercomeslorlatinibresistanceinalkrearrangedcancer AT norikoyanagitani gilteritinibovercomeslorlatinibresistanceinalkrearrangedcancer AT tomokoohhara gilteritinibovercomeslorlatinibresistanceinalkrearrangedcancer AT kanawatanabe gilteritinibovercomeslorlatinibresistanceinalkrearrangedcancer AT keiichitamai gilteritinibovercomeslorlatinibresistanceinalkrearrangedcancer AT lucfriboulet gilteritinibovercomeslorlatinibresistanceinalkrearrangedcancer AT kazuhirokatayama gilteritinibovercomeslorlatinibresistanceinalkrearrangedcancer AT biaoma gilteritinibovercomeslorlatinibresistanceinalkrearrangedcancer AT yokosasakura gilteritinibovercomeslorlatinibresistanceinalkrearrangedcancer AT yukarisagae gilteritinibovercomeslorlatinibresistanceinalkrearrangedcancer AT mutsukokukimotoniino gilteritinibovercomeslorlatinibresistanceinalkrearrangedcancer AT mikakoshirouzu gilteritinibovercomeslorlatinibresistanceinalkrearrangedcancer AT satoshitakagi gilteritinibovercomeslorlatinibresistanceinalkrearrangedcancer AT sirosimizu gilteritinibovercomeslorlatinibresistanceinalkrearrangedcancer AT makotonishio gilteritinibovercomeslorlatinibresistanceinalkrearrangedcancer AT yasushiokuno gilteritinibovercomeslorlatinibresistanceinalkrearrangedcancer AT naoyafujita gilteritinibovercomeslorlatinibresistanceinalkrearrangedcancer AT ryoheikatayama gilteritinibovercomeslorlatinibresistanceinalkrearrangedcancer
_version_	1718393385674342400

Gilteritinib overcomes lorlatinib resistance in ALK-rearranged cancer

Ejemplares similares